Using antibodies to target cancer therapeutics

Area of Science:

• Oncology
• Immunotherapy
• Radiopharmaceuticals

Background:

• Radiolabeled antibodies demonstrated selective tissue localization over 50 years ago based on unique antigen expression.
• Antibodies have become the standard targeting agents, influencing the development of non-antibody targeting compounds.

Purpose of the Study:

• To review the transformative impact of antibodies in cancer detection and treatment.
• To highlight the growing demand for both unconjugated antibodies and novel antibody conjugates.

Main Methods:

• Review of current research and clinical applications of antibody-based cancer therapies.
• Discussion of various antibody formats including unconjugated antibodies, antibody drug conjugates, immunotoxins, and radioimmunoconjugates.
• Exploration of emerging areas such as antibody-targeted cytokines and biological response modifiers.

Main Results:

• Significant interest in antibody drug conjugates and immunotoxins has grown substantially.
• Active research continues in radioimmunoconjugates for imaging and therapy, especially with alpha-emitters.
• Development of antibody-targeted cytokines and other biological response modifiers is ongoing.

Conclusions:

• The expanding pipeline of novel antibody-targeted agents undergoing clinical development indicates a promising future.
• Antibody-targeted compounds are poised to play an increasingly significant role in clinical oncology.